Published in final edited form as:

Cell Mol Life Sci. 2014 November ; 71(22): 4387–4392. doi:10.1007/s00018-014-1702-4.

The impact of HIV-1 on neurogenesis: Implications for HAND

Darren Ferrell, M.S.^{1,2} and Brian Giunta, M.D., Ph.D.^{1,2,3,4,*}

¹Department of Molecular Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL 33613, USA

²Department of Psychiatry and Behavioral Neurosciences, Neuroimmunology Laboratory, University of South Florida, Morsani College of Medicine, Tampa, FL, 33613, USA

³Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, FL 33613, USA

⁴James A. Haley Veterans Administration Hospital, Tampa, FL, 33612, USA

Abstract

HIV-1 infection, in addition to its destructive effects on the immune system and induction of chronic inflammation, also plays a role in the development of neurocognitive deficits. These deficits have been well characterized and defined clinically according to a number of cognitive parameters. The clinical severities of the neurocognitive deficits related to HIV-1 infection have been categorized as HIV-associated neurocognitive dementia (HAND), HIV-associated dementia (HAD), and HIV encephalitis (HIVE). Many mechanisms have been proposed as contributing factors to HAND including induction of oxidative stress in the central nervous system (CNS), chronic microglial mediated neuroinflammation, amyloid-beta (A β) deposition, disturbance in phosphorylated tau protein, toxic effects of combination antiretroviral therapy (cART), and impeded neurogenesis. In these review we focus solely on recent experimental evidence suggesting that disturbance by HIV-1 results in impairment of neurogenesis as one contributing factor to HAND. Impaired neurogenesis has been linked to cognitive deficits and other neurodegenerative disorders. This article will highlight recently identified pathological mechanisms which potentially contribute to the development of impaired neurogenesis by HIV-1 or HIV-1 associated proteins from both animal and human studies.

Keywords

HIV; neurogenesis; cognitive; Tat; gp120; hippocampus

Introduction

Since the introduction of combined antiretroviral therapy (cART) in 1996, mortality from human immunodeficiency virus 1 (HIV-1) related complications have drastically

*Corresponding Author: Brian Giunta, M.D., Ph.D, Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine, 3515 E. Fletcher Ave., MDT14, Tampa, FL 33613, USA. Tel.: +1 813 974 0616; fax: +1 813 974 1130. bgiunta@health.usf.edu.

diminished. It is now possible for patients infected with the virus to expect a dramatically increased lifespan compared to that of the pre-cART era [1]. cART regimens generally consist of combinations including two nucleoside reverse transcriptase inhibitors (NRTIs) and one protease inhibitor (PI) or two NRTIs and one non-nucleoside reverse transcriptase inhibitor (NNRTIs) [2]. Entry inhibitors, which interfere with the fusion of HIV-1 to host cells, can also be incorporated into HIV-1 treatment regimens. Entry inhibitors work by targeting CCR5, located on CD4+ lymphocytes, which is a common receptor utilized by HIV-1 for entry into the cell [3]. Reduced viral loads, opportunistic infections, increased T-cell counts have all contributed to the decreased mortality in HIV-1 patients [4].

Although cART has dramatically increased the lifespan of HIV patients, neurological problems still persist, the reasons which are still not fully understood. The prevalence of the less severe HIV-associated neurocognitive dysfunction (HAND) continues to increase in spite of the success of cART in reducing viral load and decreasing opportunistic infections [5]. Possibilities contributing to the various forms of HAND include central nervous system (CNS) entry by the virus itself, although neurons are generally not thought to be affected by the HIV-1 virus. It is supposed that activation of macrophages and microglia infected by HIV-1, which secrete neurotoxins induce neuronal apoptosis [6]. These infected macrophages and microglia produce chemokines and cytokines which affect not only neurons but astrocytes as well. Astrocytes, which normally serve as a protectant against neurons may now contribute to their damage [7]. A major culprit of neuronal apoptosis are thought to be viral proteins gp120 and Tat which induce the activation of caspases and promotes the up regulation of the death receptor Fas leading to apoptosis [8] [9]. Other possibilities include persistent neuroinflammation within in the brain owing to the fact that the CNS can serve as a reservoir for the HIV-1 [10]. Also, some degree of neurotoxicity from the cART, including but not limited to, the induction of oxidative stress and neuronal damage in the CNS have been suggested in recent studies [11–20]. Other possible contributing factors to HAND include comorbidities such as drug abuse, aging, psychiatric disorders, and other metabolic syndromes associated with the use of cART [21]. In this review we characterize the various forms of neurocognitive impairment associated with HIV-1 infection as currently categorized, as well as focus on HIV-1's effect on neurogenesis.

Neurocognitive Impairment in HIV-1 infection and AIDS

Not long after the first reports of AIDS patients in the early 1980s, clinicians began observing complications which affected the central and the peripheral nervous systems. It was noted that a number of AIDS patients developed a progressive encephalopathy resulting from HIV infection apart from other pathogens, diseases or opportunistic infections and was termed “sub-acute encephalitis” [22] [23]. The term “AIDS dementia complex” was introduced by Navia and Price in the late 1980s and elucidated the idea that AIDS dementia can be associated with motor deficits and neurological impairments may be the first evidence of HIV infection in a patient [24]. In 1991 The American Academy of Neurology AIDS Task Force established criteria defining levels of HIV-associated dementia (HAD) [25]. In 2007 US National Institute of Mental Health suggested the term “HIV-associated neurocognitive disorder” (HAND), which would encompass the entire spectrum of

neurological disorders associated with HIV-1 infection. This began with asymptomatic neurocognitive impairment (ANI), minor neurocognitive disorder (MND) and HAD [22] [26]. Patients classified as having ANI have impairment and cognitive functioning deficits in a minimum of two cognitive areas assessed by neuropsychological testing of at least five cognitive domains. ANI in and of itself does not tend to interfere with everyday functioning, and does not meet criteria for delirium and other comorbidities. The definition of MND requires at a minimum mild interference and functions of everyday living in addition to the ANI criteria. HAD, the most severe of the HAND disorders includes a severe acquired cognitive impairment with significant difficulty in everyday functioning. As in other stages, HAD is not explained by other disorders or forms of dementia [22] [26].

Adult Neurogenesis

Although it was once thought to be a process which ceased prenatally, it is now well accepted that the birth of new neurons, or neurogenesis, occurs in the adult mammal in both sub-ventricular zone as well as the sub-granular zone of the dentate gyrus of the hippocampus [27]. Neurogenesis occurs in multiple steps and comprises the proliferation and division of multipotent non-differentiated neural progenitor cells (NPC). These non-differentiated NPCs then give rise to the major cells of the brain including neurons, astroglia, and oligodendrocytes [28]. Microglia, the resident macrophages of the brain, are excluded from these lines as they are mesoderm derived and non-neural in lineage. The hippocampus plays a major role in memory, learning, and emotion. Further, it has been shown that changes to the hippocampus are associated with neurodegenerative and psychiatric disorders [29] [30]. The hippocampus, which is vital to learning and memory has been shown to be particularly susceptible to inflammatory insult owing to its density of receptors for inflammatory mediation [29]. Therefore it could be suggested that inflammatory insult to the CNS affecting the hippocampus could have detrimental effects on the vital roles of the hippocampus including declarative memory, spatial memory, learning, emotion, and synaptic plasticity [29]. Many technical advances in laboratory methods in the 1990s including advancements and immunohistological techniques, and confocal microscopy led to further understanding of the process of adult neurogenesis. [31].

As noted by Green et al., embryonic neurogenesis forms the structure of the hippocampus and establishes the foundation for its role in later life. The purpose of adult neurogenesis has yet not been fully understood. It has been proposed that new neurons in the hippocampus are involved in the storage and retrieval of new memories [29] [32]. Increasing research tends to show the new neurons functionally integrate into existing neural circuits [32]. A loss of new neurons in this scenario could clearly underlie the symptoms of short term memory recall seen in HAND.

Modulation of neurogenesis by HIV-1

Neurogenesis, the proliferation migration and differentiation of NPCs (NPC), is affected in neurodegenerative diseases but the exact mechanism by which neurogenesis is hampered during HAND is yet to be fully understood [33]. C-X-C chemokine receptor 4 (CXCR4), also known as fusin or CD184 is an α -chemokine receptor which is specific for stromal-

derived-factor-1 (SDF-1, also known as CXCL12), and is a potent chemokine for lymphocytes. This receptor is one of many chemokine receptors which HIV can utilize to infect CD4+ T cells [34]. CXCR4 is known to be present in newborn neurons during embryogenesis and throughout adulthood where it plays a significant role in neuronal guidance. As neurons mature, levels of this receptor decrease. Research has shown that CXCR4 mutant mice have aberrant neuronal distribution, and deleterious CXCR4 have been associated with neurological disorders such as epilepsy [35]. As Kaul notes, this is indicative of a potential for HIV-1 and its envelope protein gp120 to directly inhibit or interfere with the functions of neural stem and progenitor cells [36].

Additionally, although it is known that HIV-1 does not infect primary neurons researchers have shown that neural stem cells can be infected by the HIV-1 virus [37]. In an *in vitro* study by Lawrence and colleagues, this group showed that immature NPC's were also subject to infection in addition to other previously known infectable glia such as astrocytes and microglia. This further bolstered the evidence that systemic HIV-1 infection can lead to infection in NPC's, hampering neurogenesis [37]. In addition, research by Schwartz, et. al., showed that in the pre-cART era, pediatric, *post-mortem* brain tissue had HIV-1 infection of NPC's. This suggests that early infection and lack of cART may be a contributing factor to the reduction of neurogenesis which may lead to neurocognitive dysfunction later in life [38]. Furthermore, infection of NPCs by HIV-1 initiated quiescence via CXCR4 and CCR5 [39]. As Kaul further notes, *postmortem* brain tissue from HAD patients had fewer adult NPCs in the DG than did non-demented and non-infected control specimens [36] [39]. Also in his experiments, it was demonstrated that *in vitro* treatment with HIV-1/gp120 significantly reduced the proliferation of adult progenitor cells, and also lead to a reduction in the proliferation of neural progenitors in the hippocampus compared to control specimens [7]. This was found to be due to an inhibition of NPC proliferation to the activation of the p38MAPK pathway which activated protein kinase 2 causing arrest of the cell cycle in the G1 phase [36] [7].

Recent research has explored experimentally HIV-1's detrimental effects on neurogenesis by a myriad of experimental designs. Peng et al., tested the hypothesis that HIV-1 infection or immune activated brain macrophages significantly affected NPC proliferation and differentiation by the regulation of cytokines [33]. They found that media conditioned with lipopolysaccharide (LPS)-activated monocyte-derived macrophages (MDM) (LPS-MDM) or media containing HIV-infected MDM conditioned media (MCM) prompted an intense increase in NPC proliferation. Furthermore they found that LPS-MCM and HIV+ LPS-MCM significantly decreased beta-III-tubulin and increased glial fibrillary acidic protein (GFAP) which demonstrated and induction of gliogenesis and a decrease in neurogenesis [33].

In an investigation by Mishra, et al., human NPC's were cultured both in the presence and absence of HIV-1 Tat to investigate whether HIV-1 viral proteins can alter the properties of human NPC's. In their experiments, they utilized cellular proliferation assays including BrdU and Ki67 staining as well as well cDNA and protein arrays. Their data revealed that HIV-1 Tat protein severely affected the proliferation of NPCs evidenced by lower BrdU and

Ki67 staining. Furthermore they discovered that HIV-1 Tat hampered neurogenesis evidence by decreased numbers of Tuj-1 and doublecortin-positive cells [40].

Lee et al., demonstrated a significant reduction in the perforation of hippocampal NPC's in the dentate gyrus of adult animals in transgenic mice models of HIV neurologic disease with glial expression of the HIV envelope protein gp120. They identified gp120 first affected amplifying NPCs (ANPs) and also demonstrated that in the presence of gp120, newly generated neurons exhibited irregular dendritic development [41]. This group also found that exercise and treatment with selective serotonin reuptake inhibitors (SSRIs) increased ANP populations and rescued deficits in gp120 transgenic mice [41].

Das and Basu also noted that viral infections during pregnancy and perinatal commonly cause malformations of brain development. These infections may affect CNS development and result in long-term cognitive deficits. As they show, both HIV and herpes virus infect the neural NPC, and over extended periods of time reactivation of virus may occur even later in life. In this case the virus-infected NPC may undergo cell-cycle arrest, leading to impaired neurogenesis. These disturbances of neurogenesis post viral infection have direct and damaging implications in viral pathogenesis and long-term neurocognitive deficits in infected individuals [42].

As Peng and colleagues note, in HAD, immune-activated brain mononuclear phagocytes are the driving force of CNS inflammation which is alleged to inhibit neurogenesis [43]. In their previous work, they showed that HIV-1 infected and LPS activated monocyte-derived macrophages (MDM) inhibited NPC neurogenesis and enhanced astrogliogenesis *via* the secretion of pro-inflammatory cytokines including TNF- α [33]. In a more recent study, the same group showed that LPS-activated medium conditioned with MDM and HIV-infected/LPS activated MDM-conditioned media prompted janus associated kinase (JAK) 1/ signal transducer and activator of transcription (STAT) 3 activation which was associated with an increase in glial fibrillary acidic protein (GFAP), a marker of astrogliogenesis. In sum, these studies show a strong link between inflammation of the brain and impedance of neurogenesis which has far reaching implications for the treatment of HAND [43].

It has been reported that growth factors such as platelet derived growth factor-BB (PDGF-BB) supply the neurons in the CNS with tropic support. In a study by Yao and colleagues, they sought to determine whether PDGF-BB regulated neurogenesis within the context of HAND and drugs of abuse [44]. They demonstrated that pretreatment of rat hippocampal NPCs with PDGF-BB restored NPC proliferation which had been damaged by HIV Tat-cocaine. In their model, they found that the transient receptor potential canonical (TRPC) channels in PDGF-BB mediated the proliferation of NPCs [44]. They further substantiated their findings *in vivo* utilizing Tat transgenic mice by showing that the hippocampal injection of recombinant adeno-associated virus (AAV) 2-PDGF-2 rescued impaired NPC proliferation that was induced by Tat-cocaine. These findings identified the TRPC1 channel as a novel target which regulates cell proliferation via PDGF-BB and implies there exists a therapeutic potential for impaired neurogenesis induced by Tat and cocaine [44].

Gorantla, et. al., also demonstrated that hippocampal damage by HIV-1 encephalitis in murine models could be partially restored by the administration of Copolymer-1 (COP-1). They showed that COP-1 exerts a strong neuroprotective effect by suppressing microglial inflammatory response, which occurs in HIVE. In their study, they were able to partially restore hippocampal neurogenesis, in addition to mitigating pro-inflammatory cytokine release which included TNF- α and IL-1 β . Their experiments showed a possible therapeutic value of COP-1 in HAND including NPC ablation by HIV-1 and associated viral proteins [45].

The role of apolipoprotein allelic variants in innate immune responses of maturing human neuroepithelial progenitor cells exposed to HIV-1 was explored by Geffin and colleagues. In their study, they utilized a model system consisting of human neuroepithelial progenitor (NEP) that differentiated into both neurons and astrocytes in vitro [46]. The researchers utilized gene expression microarrays to determine a group of genes that were specifically upregulated by exposure to HIV-1, and were strongly influencing interferon induced responses. Their findings showed that in the apolipoprotein E3/E3 genotype the innate immune response was significantly stronger than in the E3/E4 variant. Their findings suggested that maturing NEP cells respond to HIV and mount a varying innate immune response based upon the apolipoprotein genotype of the cells [46].

It has also been suggested that, along with diminished neuronal survival and genesis, abridged neuronal connections may play a role in the reduced neurogenesis associated with HAND. As Mocchetti and colleagues note, this occurrence should no ensue in the adult developing brain in as much as synaptic plasticity is promoted by neurotrophic factors [47]. In a comprehensive review, these researchers outlined a number of neurotrophic factors and their role in the mediation of neurotoxins which interfere with cellular death pathways in a number of neurodegenerative diseases [47]. As they note, neurotrophic factors promote the growth of axons and infer that the pathologies of HAND serve as excellent candidates for therapies based on neurotrophic factors. Fibroblast growth factors (FGFs), brain derived growth factors (BDNFs), glial cell-derived neurotrophic growth factor (GDNFs), platelet-derived growth factors (PDGFs) as well as neurotrophins are all potential therapeutic targets for the mediation of HAND [47].

In an interesting study by Lee, et. al., these researchers found HAND is frequently accompanied by atrophy of the brain including the inhibition of neurogenesis and the growth of neuritis, especially in the hippocampus. This is suggested to contribute to cognitive dysfunction as noted above. Utilizing a gp120 mouse model, they showed that running exercise stimulated the NPC proliferation in the dentate gyrus. The exercise also showed increased survival of existing cells as well as generation of new NPCs. They also showed that on a molecular level the sustained exercise increased BDNF in the hippocampus reduced the over activation of cyclin-dependent kinase 5 (Cdk5). It can be concluded from their work therefore that increasing BDNF and arresting the over activation of Cdk5 can rescue the impairment of adult neurogenesis caused by HIV-1 infection [48].

In previous work, it was that platelet-derived growth factor-BB (PDGF-BB) upregulated the proliferation of rat NPCs [49]. More recently however, they showed that if NPCs were pre-

treated with PDGF-BB, they were able to restore Tat-mediated NPC proliferation impairment. They showed this occurred via the activation of p38 and the c-jun N-terminal kinase (JNK)/mitogen associated protein kinase (MAPK) pathways. Interestingly, they also showed that the same pre-treatment prompted inactivation of glycogen synthase kinase- β (GSK-3 β), which they showed by increased levels of its inhibitory phosphorylation at Ser9. Furthermore, this experiment evidenced that nuclear β -catenin, which is a primary substrate of GSK-3 β , increased in the PDGF-BB group. This further support the hypothesis that GSK-3 β / β -catenin represent potential targets of NPC regulation and proliferation and may offer possible rescue interventions of Tat-induced neurogenesis impairment [50].

In a recent study by Avraham and colleagues, it was examined whether the deletion of the fatty acid amide hydrolase enzyme (FAAH), which regulates the degradation of the endocannabinoid lipid ligands, which play a role in regulating neural functions, could affect gp120's inhibition of neurogenesis in gp120 transgenic mice. They found that, in fact, the genetic knockout of FAAH in the gp120 mice showed significant decreases in astrogliosis, and gliogenesis, which was accompanied by increase in neurogenesis. This, they concluded was a result of the creation of new NPC niches in the transgenic mice. This indicates a possible future therapeutic pathway to treat the inhibition of neurogenesis in brain infected by HIV-1 [51].

Conclusion

Taken together, these studies show a strong link between HIV-1 and especially its secretion of proteins gp120 and Tat with reduced neurogenesis. Since HAND is frequently accompanied by atrophy of the brain including the inhibition of neurogenesis and the growth of neuritis, especially in the hippocampus, this disturbance in neurogenesis could be an underlying factor in its development. HIV mediated reductions in neurogenesis are subserved by a variety of pathways including p38, JNK, MAPK, and GSK-3 β . Thus amelioration of HIV induced disruption of neurogenesis could be an important therapeutic target for future pre-clinical and clinical studies.

References

1. Lima VD, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. *AIDS*. 2007; 21(6):685–92. [PubMed: 17413689]
2. Quashie PK, Mesplede T, Wainberg MA. HIV Drug Resistance and the Advent of Integrase Inhibitors. *Curr Infect Dis Rep*. 2013; 15(1):85–100. [PubMed: 23180144]
3. Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. *Clin Ther*. 2008; 30(7):1228–50. [PubMed: 18691983]
4. Del Guerra FB, et al. Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways. *J Neurovirol*. 2013; 19(4):314–27. [PubMed: 23868513]
5. Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. *Semin Neurol*. 2007; 27(1):86–92. [PubMed: 17226745]
6. Adle-Biassette H, et al. Neuronal apoptosis in HIV infection in adults. *Neuropathol Appl Neurobiol*. 1995; 21(3):218–27. [PubMed: 7477730]

7. Okamoto S, et al. HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cell-cycle withdrawal and G1 arrest. *Cell Stem Cell*. 2007; 1 (2):230–6. [PubMed: 18371353]
8. Thomas S, Mayer L, Sperber K. Mitochondria influence Fas expression in gp120-induced apoptosis of neuronal cells. *Int J Neurosci*. 2009; 119(2):157–65. [PubMed: 19125371]
9. Kruman II, Nath A, Mattson MP. HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. *Exp Neurol*. 1998; 154(2):276–88. [PubMed: 9878167]
10. Vissers M, Stelma FF, Koopmans PP. Could differential virological characteristics account for ongoing viral replication and insidious damage of the brain during HIV 1 infection of the central nervous system? *J Clin Virol*. 2010; 49(4):231–8. [PubMed: 20833583]
11. Apostolova N, Blas-Garcia A, Esplugues JV. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-gamma inhibition. *Trends Pharmacol Sci*. 2011; 32 (12):715–25. [PubMed: 21899897]
12. Apostolova N, Blas-Garcia A, Esplugues JV. Mitochondrial toxicity in HAART: an overview of in vitro evidence. *Curr Pharm Des*. 2011; 17(20):2130–44. [PubMed: 21718249]
13. Apostolova N, et al. Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy. *Hepatology*. 2011; 54(3):1009–19. [PubMed: 21626526]
14. Zhou L, Saksena NK. HIV Associated Neurocognitive Disorders. *Infect Dis Rep*. 2013; 5(Suppl 1):e8. [PubMed: 24470972]
15. Blas-Garcia A, Apostolova N, Esplugues JV. Oxidative stress and mitochondrial impairment after treatment with anti-HIV drugs: clinical implications. *Curr Pharm Des*. 2011; 17(36):4076–86. [PubMed: 22188456]
16. Blas-Garcia A, Esplugues JV, Apostolova N. Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity. *Curr Med Chem*. 2011; 18(14):2186–95. [PubMed: 21521162]
17. Brown LA, et al. Efavirenz Promotes beta-Secretase Expression and Increased Abeta1-40,42 via Oxidative Stress and Reduced Microglial Phagocytosis: Implications for HIV Associated Neurocognitive Disorders (HAND). *PLoS One*. 2014; 9(4):e95500. [PubMed: 24759994]
18. Giunta B, et al. Antiretroviral medications disrupt microglial phagocytosis of beta-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. *Mol Brain*. 2011; 4(1):23. [PubMed: 21649911]
19. Manda KR, et al. Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. *Free Radic Biol Med*. 2011; 50(7):801–10. [PubMed: 21193030]
20. Akay C, et al. Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. *J Neurovirol*. 2014; 20(1):39–53. [PubMed: 24420448]
21. Alfahad TB, Nath A. Update on HIV-associated neurocognitive disorders. *Curr Neurol Neurosci Rep*. 2013; 13(10):387. [PubMed: 23954972]
22. Rosca EC, et al. HIV-associated neurocognitive disorders: a historical review. *Neurologist*. 2012; 18(2):64–7. [PubMed: 22367830]
23. Snider WD, et al. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. *Ann Neurol*. 1983; 14(4):403–18. [PubMed: 6314874]
24. Navia BA, Price RW. The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. *Arch Neurol*. 1987; 44(1):65–9. [PubMed: 3800724]
25. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. *Neurology*. 1991; 41(6):778–85. [PubMed: 2046917]
26. Antinori A, et al. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology*. 2007; 69(18):1789–99. [PubMed: 17914061]
27. Lacar B, et al. Increasing the resolution of the adult neurogenesis picture. *F1000Prime Rep*. 2014; 6:8. [PubMed: 24592320]

28. Gage FH, Temple S. Neural stem cells: generating and regenerating the brain. *Neuron*. 2013; 80(3):588–601. [PubMed: 24183012]
29. Green HF, Nolan YM. Inflammation and the developing brain: Consequences for hippocampal neurogenesis and behavior. *Neurosci Biobehav Rev*. 2014; 40C:20–34. [PubMed: 24462889]
30. Frisoni GB, et al. Mapping local hippocampal changes in Alzheimer's disease and normal ageing with MRI at 3 Tesla. *Brain*. 2008; 131(Pt 12):3266–76. [PubMed: 18988639]
31. Kempermann G, Kuhn HG, Gage FH. More hippocampal neurons in adult mice living in an enriched environment. *Nature*. 1997; 386(6624):493–5. [PubMed: 9087407]
32. Schinder AF, Gage FH. A hypothesis about the role of adult neurogenesis in hippocampal function. *Physiology (Bethesda)*. 2004; 19:253–61. [PubMed: 15381753]
33. Peng H, et al. HIV-1-infected and/or immune-activated macrophage-secreted TNF-alpha affects human fetal cortical neural progenitor cell proliferation and differentiation. *Glia*. 2008; 56(8):903–16. [PubMed: 18383342]
34. Tamamis P, Floudas CA. Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop. *Biophys J*. 2013; 105(6):1502–14. [PubMed: 24048002]
35. Bagri A, et al. The chemokine SDF1 regulates migration of dentate granule cells. *Development*. 2002; 129(18):4249–60. [PubMed: 12183377]
36. Kaul M. HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis. *Front Biosci*. 2008; 13:2484–94. [PubMed: 17981728]
37. Lawrence DM, et al. Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. *J Virol*. 2004; 78(14):7319–28. [PubMed: 15220405]
38. Schwartz L, et al. Evidence of human immunodeficiency virus type 1 infection of nestin-positive neural progenitors in archival pediatric brain tissue. *J Neurovirol*. 2007; 13(3):274–83. [PubMed: 17613718]
39. Krathwohl MD, Kaiser JL. HIV-1 promotes quiescence in human neural progenitor cells. *J Infect Dis*. 2004; 190(2):216–26. [PubMed: 15216454]
40. Mishra M, et al. Human immunodeficiency virus type 1 Tat modulates proliferation and differentiation of human neural precursor cells: implication in NeuroAIDS. *J Neurovirol*. 2010; 16(5):355–67. [PubMed: 20839920]
41. Lee MH, et al. Rescue of adult hippocampal neurogenesis in a mouse model of HIV neurologic disease. *Neurobiol Dis*. 2011; 41(3):678–87. [PubMed: 21146610]
42. Das S, Basu A. Viral infection and neural stem/progenitor cell's fate: implications in brain development and neurological disorders. *Neurochem Int*. 2011; 59(3):357–66. [PubMed: 21354238]
43. Peng H, et al. HIV-1-infected and immune-activated macrophages induce astrocytic differentiation of human cortical neural progenitor cells via the STAT3 pathway. *PLoS One*. 2011; 6(5):e19439. [PubMed: 21637744]
44. Yao H, et al. Platelet-derived growth factor-BB restores human immunodeficiency virus Tat-cocaine-mediated impairment of neurogenesis: role of TRPC1 channels. *J Neurosci*. 2012; 32(29):9835–47. [PubMed: 22815499]
45. Gorantla S, et al. Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis. *J Immunol*. 2007; 179(7):4345–56. [PubMed: 17878329]
46. Geffin R, et al. Apolipoprotein E-dependent differences in innate immune responses of maturing human neuroepithelial progenitor cells exposed to HIV-1. *J Neuroimmune Pharmacol*. 2013; 8(4):1010–26. [PubMed: 23744346]
47. Mocchetti I, et al. Implementing Neuronal Plasticity in NeuroAIDS: the Experience of Brain-derived Neurotrophic Factor and other Neurotrophic Factors. *J Neuroimmune Pharmacol*. 2014; 9(2):80–91. [PubMed: 23832285]
48. Lee MH, et al. Impaired neurogenesis and neurite outgrowth in an HIV-gp120 transgenic model is reversed by exercise via BDNF production and Cdk5 regulation. *J Neurovirol*. 2013; 19(5):418–31. [PubMed: 23982957]
49. Yang L, et al. Involvement of miR-9/MCPIP1 axis in PDGF-BB-mediated neurogenesis in neuronal progenitor cells. *Cell Death Dis*. 2013; 4:e960. [PubMed: 24336080]

50. Chao J, et al. Platelet-derived growth factor-BB restores HIV Tat -mediated impairment of neurogenesis: role of GSK-3 β /beta-catenin. *J Neuroimmune Pharmacol.* 2014; 9(2):259–68. [PubMed: 24248537]
51. Avraham HK, et al. Impaired Neurogenesis by HIV-1-Gp120 is Rescued by genetic deletion of Fatty Acid Amide Hydrolase Enzyme. *Br J Pharmacol.* 2014